Latest News - Novan

Wednesday, November 08, 2017

Novan Plans to Complete Development of SB204 Acne Candidate via Third Party Funding and Execution

Novan, Inc., has agreed in principle to a business structure that would enable further development and advancement of SB204 for the treatment of acne vulgaris via third party financing and third party…

Read the full story

Tuesday, September 26, 2017

Novan Has Guidance Meeting with FDA on SB204

Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which t…

Read the full story

Wednesday, April 12, 2017

Novan: Positive Topline Results with Fungicidal SB208 in Phase 2 Trial

Novan, Inc. has announced positive topline results from their Phase 2 clinical trial with SB208, a topical, silicone based-gel under development for the treatment of infections caused by dermatop…

Read the full story

Tuesday, April 04, 2017

Novan Forms New Advisory Council Focused on Nitric Oxide Technologies in Dermatology

Novan, Inc.  has formed an Advisory Council comprised of key opinion leaders with broad expertise in dermatology. These leading physicians will provide medical advice and drug-development insight…

Read the full story

Friday, January 27, 2017

Topline Results from Novan's SB204 Phase 3 Pivotal Trials: Inconsistent Across Trials

Novan, Inc. (NASDAQ:NOVN) today announced  top-line results from the Company’s two, replicate Phase 3 pivotal clinical trials for SB204 in the treatment of acne vulgaris. In the intent-to-t…

Read the full story

Wednesday, November 30, 2016

Novan: Significant Improvement of Genital Warts with SB206

Top-line results from Novan Inc.’s Phase 2 clinical trial with SB206 for the treatment of  genital warts caused by human papillomavirus, or HPV show statistically significant benefits, the …

Read the full story

Wednesday, November 16, 2016

Novan: SB414 Inhibited IL-17 in Psoriasis Mouse Model

Novan, Inc. has announced preclinical data showing that its nitric oxide-releasing product candidate SB414 significantly (p<0.05) reduced composite psoriasis scores, which consist of eryt…

Read the full story

Wednesday, October 19, 2016

Novan: Phase 2b Data for SB204 Gel to be Presented at Fall Clinical Dermatology Conference

Results from Novan’s Phase 2b clinical trial to evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 gel for the treatment of acne vulgaris will be presente…

Read the full story

Wednesday, September 21, 2016

Novan, Inc. Launches IPO, Lists on NASDAQ

Novan, Inc. (the “Company” or “Novan”) today announced the pricing of the Company’s initial public offering of 4,100,000 shares of common stock at a price to the public o…

Read the full story